Sanofi announced a definitive agreement to acquire Blueprint Medicines Corporation, a U.S.-based biopharmaceutical company focused on systemic mastocytosis (SM) and other KIT-driven diseases. This strategic acquisition will significantly bolster Sanofi’s rare immunology pipeline with a portfolio of innovative medicines, including Ayvakit/Ayvakyt (avapritinib) and multiple promising development-stage assets.
The transaction brings Ayvakit/Ayvakyt-currently the only approved therapy for both advanced systemic mastocytosis (ASM) and indolent systemic mastocytosis (ISM)—into Sanofi’s portfolio. Approved in both the U.S. and EU, Ayvakit/Ayvakyt addresses a debilitating rare disease marked by abnormal mast cell accumulation and activation in the bone marrow, skin, gastrointestinal tract, and other organs.
In addition to Ayvakit/Ayvakyt, the acquisition includes a robust pipeline with next-generation candidates such as elenestinib, and BLU-808—a highly selective oral wild-type KIT inhibitor with potential to treat a wide range of immunological conditions. The integration of Blueprint’s deep expertise and relationships with allergists, dermatologists, and immunologists is expected to further expand Sanofi’s capabilities and reach in the immunology space.
Also Read: Danaher and AstraZeneca Forge Strategic Partnership to Advance AI-Driven Precision Medicine
Under the terms of the agreement, Sanofi will acquire all outstanding shares of Blueprint for $129.00 per share in cash at closing, valuing the transaction at approximately $9.1 billion in equity. In addition, Blueprint shareholders will receive a non-tradeable contingent value right (CVR), allowing for two potential milestone payments: $2 and $4 per CVR, contingent upon the achievement of specific development and regulatory milestones for BLU-808. Including these potential payments, the total transaction value could reach approximately $9.5 billion on a fully diluted basis.
This acquisition underscores Sanofi’s commitment to advancing precision medicine in immunology by targeting the underlying biology of complex rare diseases. The addition of Blueprint’s expertise and novel therapies is expected to play a transformative role in how patients with systemic mastocytosis and related KIT-driven diseases are diagnosed and treated.